ChinaAMC Hangzhou Heda Hi-Tech Development Industrial Park Closed Infrastructure Real Estate Investment Trust Registered Unit
SSZSE:1801031.56
CNY
-0.02
(-1.52%)
ISIN
CNE100005SH1
Return %
Stock
S&P 500
1Y
-30.65
13.14
3Y
-39.69
80.78
5Y
- -
67.74
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Miscellaneous
- Industry
- Investment trusts
- Address
- Beijing China
- Similar Companies
- Business
- ChinaAMC Hangzhou Heda Hi-Tech Development Industrial Park Closed Infrastructure Real Estate Investment Trust is a China-based publicly traded closed-end infrastructure real estate investment trust managed by China Asset Management Co., Ltd. and sponsored by Hangzhou Heda Hi-Tech Development Group Co., Ltd. Established in 2022 and headquartered in Hangzhou, Zhejiang Province, the trust focuses on the investment, ownership, and operation of high-tech and life science industrial park real estate assets within the Hangzhou Qiantang New Area. The trust's core products and services encompass specialized industrial property leasing and integrated park management operations, which systematically include biopharmaceutical research and development laboratory leasing; high-tech office building leasing; state-level enterprise incubation and startup acceleration spaces; standardized production and pilot testing workshops; auxiliary commercial and retail facility leasing; talent apartment accommodation services; comprehensive property management and facility maintenance; and customized operational support services for tenant enterprises. The trust's underlying asset portfolio is anchored by the Heda Incubator Project, which provides specialized incubation infrastructure for emerging tech ventures, and the Heda Medicine Valley Phase I Project, located in the Hangzhou Medical Port to support biopharmaceutical and medical device enterprises across research, development, and commercialization phases. Its target market primarily comprises domestic and international biopharmaceutical corporations, medical technology innovators, clinical research institutions, life science startups, and high-tech enterprises. In recent developments, sponsor Hangzhou Heda Hi-Tech Development Group Co., Ltd. completed an on-market increase in its trust unit holdings to enhance capital alignment and long-term asset value. Furthermore, the fund manager executed ongoing lease optimization initiatives and tenant retention campaigns to maintain occupancy stability across its biomedical real estate assets, implemented key fund manager adjustments to streamline portfolio governance, and completed scheduled cash distribution payouts to unit holders.